Safety and Efficacy of Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants
Phase 1/Phase 2
3 Years
65 Years
3 Years
65 Years
Open (Enrolling)
Both
Graft Versus Host Disease
Both
Graft Versus Host Disease
Trial Information
Safety and Efficacy of Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants
Inclusion Criteria
Eligible for full intensity bone marrow transplant (BMT) conditioning but who lack a 6/6
HLA idential sibling donor
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Prevention
Principal Investigator
John Levine, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Univeristy of Michigan
Authority:
United States: Food and Drug Administration
Study ID:
2146
NCT ID:
NCT00056875
Start Date:
September 2002
Completion Date:
April 2004
Related Keywords:
- Graft Versus Host Disease
- graft versus host disease
- bone marrow transplant
- alternative donor
- Graft vs Host Disease
Name | Location |
|---|---|
| University of Michigan Cancer Center | Ann Arbor, Michigan 48109 |
